All In Biotech

Drug Trial Radar · NCT01626664

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

71

Actual

Start

Jun 2012

Primary completion

Aug 2015

Study completion Feb 2018

Sponsor

Lead sponsor
Kyowa Kirin, Inc.Industry
Sponsor type
Industry
First posted
Jun 25, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to estimate the overall response rate of subjects with relapsed or refractory Adult T-cell Leukemia-Lymphoma (ATL).

Conditions

  • Adult T-cell Leukemia-Lymphoma

Interventions

  • KW-0761Biological

    1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression

  • PralatrexateDrug

    30 mg/m2 weekly for 3 weeks followed by 1 week of no therapy until progression

  • gemcitabine plus oxaliplatinDrug

    gemcitabine 1000 mg/m2, followed by oxaliplatin 100 mg/m2 every 2 weeks until progression

  • DHAPDrug

    dexamethasone 40 mg on Day 1-4, cisplatin 100 mg/m2 on Day 1 followed by 2 doses of cytarabine 2000 mg/m2 every 4 weeks until progression

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: every 8 weeks from date of randomization until the date of first documented progression or date of death from any cause, whichever came first

Locations

20 sites in 6 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of Miami / Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Northwestern University

    Chicago, Illinois

  • National Cancer Institute

    Bethesda, Maryland

  • Washington University School of Medicine

    St Louis, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Memorial Sloan Kettering

    New York, New York

  • Columbia Presbyterian

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Hospital Universitario Professor Edgard Santos- UFBA

    Salvador, Bahia, Brazil

  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

    Sao Paulo- SP, Brazil

  • CHU de Fort de France

    Fort de France Cedex, France

  • Hospital Necker

    Paris, France

  • Hospital Nacional Edgardo Rebagliati Martins

    Lima, Peru

  • Instituto Oncologico Miraflores

    Lima, Peru

  • Guy's Hospital

    London, United Kingdom

  • Imperial College

    London, United Kingdom

  • Sandwell General Hospital

    West Midlands, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.